Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its Deramiocel cell therapy between December 2025 and July 2026. The FDA's briefing documents criticized the company's statistical analysis methods, and an advisory panel voted 9-3 against the therapy's efficacy, causing the stock to plummet 62% on July 27, 2026. Investors who purchased shares during the class period are urged to file claims by September 28, 2026.